Dashboard
Manage Tickers

KPTI


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
08/07/2024 20:15:08

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $7 pr...

rbc-capital-reiterates-outperform-on-karyopharm-therapeutics-maintains-3-price-target
RBC Capital Reiterates Outperform on Karyo...
08/07/2024 16:23:15

RBC Capital analyst Brian Abrahams reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and maintains $3 price...

baird-maintains-outperform-on-karyopharm-therapeutics-lowers-price-target-to-5
Baird Maintains Outperform on Karyopharm T...
08/07/2024 15:49:11

Baird analyst Mitch Collett maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target fr...

karyopharm-revises-fy24-total-revenue-outlook-from-140m---160m-to-145m---160m-est-14544m
Karyopharm Revises FY24 Total Revenue Outl...
08/06/2024 11:35:01

karyopharm-therapeutics-q2-2024-gaap-eps-020-beats-030-estimate-sales-42786m-beat-36179m-estimate
Karyopharm Therapeutics Q2 2024 GAAP EPS $...
08/06/2024 11:32:59

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate ...

hc-wainwright--co-maintains-buy-on-karyopharm-therapeutics-lowers-price-target-to-7
HC Wainwright & Co. Maintains Buy on Karyo...
06/28/2024 17:28:55

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
06/03/2024 10:26:09

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...

karyopharm-on-saturday-presented-updated-exploratory-subgroup-analyses-from-siendo-study-on-advanced-or-recurrent-tp53-wild-type-endometrial-cancer-at-asco-2024
Karyopharm On Saturday, Presented Updated ...
06/02/2024 18:37:52

karyopharm-therapeutics-files-for-shelf-registration-of-up-to-458m-shares-of-common-stock-by-selling-stockholders
Karyopharm Therapeutics Files For Shelf Re...
05/30/2024 20:48:20

- SEC Filing

hc-wainwright--co-reiterates-buy-on-karyopharm-therapeutics-maintains-8-price-target
HC Wainwright & Co. Reiterates Buy on Kary...
05/09/2024 10:53:41

HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...

karyopharm-announces-refinancing-transactions-148m-of-existing-convertible-notes-due-in-2025-to-be-exchanged-for-111m-of-new-convertible-notes-due-in-2029-and-warrants-issues-new-100m-senior-secured-term-loan-due-in-2028a
Karyopharm Announces Refinancing Transacti...
05/08/2024 11:39:20

karyopharm-therapeutics-reaffirms-2024-revenue-guidance-of-140m-160m-versus-consensus-of-14652m-including-us-xpovio-net-product-revenue-guidance-of-100m-120m
Karyopharm Therapeutics Reaffirms 2024 Rev...
05/08/2024 11:39:20

karyopharm-therapeutics-q1-2024-gaap-eps-032-beats-033-estimate-sales-33126m-miss-34473m-estimate
Karyopharm Therapeutics Q1 2024 GAAP EPS $...
05/08/2024 11:38:06

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate ...

karyopharm-announces-presentations-in-endometrial-cancer-and-myelofibrosis-at-the-2024-american-society-of-clinical-oncology-annual-meeting
Karyopharm Announces Presentations In Endo...
04/24/2024 20:42:32

Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"...

onco360-selected-as-the-preferred-national-specialty-pharmacy-partner-for-karyopharms-product-xpovio-a-first-in-class-xpo-1-inhibitor
Onco360 Selected As The Preferred National...
03/13/2024 20:38:15

Onco360®, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Ka...

hc-wainwright--co-maintains-buy-on-karyopharm-therapeutics-lowers-price-target-to-8
HC Wainwright & Co. Maintains Buy on Karyo...
03/01/2024 12:10:52

HC Wainwright & Co. analyst Edward White maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and lowers the price...

karyopharm-sees-2024-total-revenue-140m-160m-vs-15202m-est
Karyopharm Sees 2024 Total Revenue $140M-$...
02/29/2024 12:31:56

karyopharm-therapeutics-q4-2023-gaap-eps-036-misses-030-estimate-sales-3375m-miss-3540m-estimate
Karyopharm Therapeutics Q4 2023 GAAP EPS $...
02/29/2024 12:31:15

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimat...

earnings-scheduled-for-february-29-2024
Earnings Scheduled For February 29, 2024
02/29/2024 10:15:24

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

karyopharm-therapeuticss-earnings-a-preview
Karyopharm Therapeutics's Earnings: A Preview
02/28/2024 19:01:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION